The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: results from the EORTC 22922/10925 randomised trial.
Fiche publication
Date publication
mai 2022
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PEIGNAUX Karine
Tous les auteurs :
Kaidar-Person O, Fortpied C, Hol S, Weltens C, Kirkove C, Budach V, Peignaux-Casasnovas K, van der Leij F, Vonk E, Valli M, Weidner N, Guckenberger M, Koiter E, Fourquet A, Bartelink H, Struikmans H, Poortmans P,
Lien Pubmed
Résumé
The multicentre EORTC 22922/10925 trial (ClinicalTrials.gov, NCT00002851) was conducted between 1996 and 200. The trial evaluated the effect of irradiation of the internal mammary and medial supraclavicular lymph node chains (IM-MS) vs no further therapy on survival and cause of death in breast cancer stage I-III patients. At 15.7 years of median follow-up, a significant reduction of breast cancer specific mortality (BCSM) and any recurrence, not translating in improved overall survival (OS), and low absolute rates of side effects were found. The aim of the current analysis was to evaluate the association of radiation therapy (RT) techniques of IM-MS lymph node irradiation with long-term outcomes.
Mots clés
Breast cancer, EORTC, Lymph nodes, Quality assurance, Radiotherapy, Randomised trial, Techniques, Treatment planning
Référence
Radiother Oncol. 2022 05 11;: